Companies

GROUP
STRUCTURE

Swiss Rockets AG

Umbrella company and incubator

Next-generation vaccines

Targeted cancer therapies

Targeted cancer radiotherapies

SUMMARY
OF MAIN
SUBSIDIARIES

SOLUTION UNMET NEED THERAPEUTIC AREA
  • THERAPEUTIC AREA

    Infectious diseases, new COVID-19 variants

  • UNMET NEED

    Lack of broad and long-lasting immunity against variants of concern, effective prevention of re-infection and reduction of COVID-19 and Long-COVID-19 cases.

  • SOLUTION

    Easy intranasal needle-free COVID-19 vaccine administration that induces robust immune responses, easily scalable logistics.

  • THERAPEUTIC AREA

    Actinic Keratosis (topical), Prostate Cancer and Head and Neck Cancer (oral)

  • UNMET NEED

    The standard of care for some of the most common cancers as well as AK lack are still an unmet medical need (lack of efficacy and tolerability).

  • SOLUTION

    By leveraging the differentiated dual-PI3K/mTOR antagonist, Torqur’s drug candidates inhibit topically the pathological development of AK as wells as head and neck cancer with a significantly improved safety profile.

  • THERAPEUTIC AREA

    Radioligand Therapy for: Prostate Cancer and other cancer types

  • UNMET NEED

    Prostate cancer is the most common cancer in male patients as many othere cancer types lack access to efficient, targeted treatments.

  • SOLUTION

    By harnessing the potential of Terbium-161, Torpedo aims to develop targeted precision medicines aimed at improving patient outcomes and quality of life.

ROCKETVAX

Next-Generation Vaccines

Rocketvax pioneers the development of innovative vaccines to combat infectious diseases, leveraging cutting-edge technology to address critical global health challenges.

Company Presentation

SUMMARY:
ROCKETVAX AG

PROBLEM

  • COVID-19 still a significant global health threat
  • Insufficient protection against emerging SARS-CoV-2 variants
  • Lack of non-injectable options vastly limits vaccine adoption

SOLUTION

    Cutting-edge Rocketvax vaccine candidates feature:

  • Long-term multifaceted immunity against current and future SARS-CoV-2 variants1
  • Local immunity at the site of virus entry (upper respiratory tissues)2
  • Reduction of both virus infection and transmission3
  • Potential to curb future COVID-19 pandemics
  • Intranasal vaccination improves access, convenience and scalability

All Preclinical Data:
1. Jakob Trimpert et al. (2021)
2. Nouailles, G., Adler, J.M. et al. (2023).
3. Adler JM, et al. (2023)

All Preclinical Data:
1. Jakob Trimpert et al. (2021)
2. Nouailles, G., Adler, J.M. et al. (2023).
3. Adler JM, et al. (2023)

Company Presentation
Company Presentation

TORQUR AG

Inovative Therapeutics

Torqur develops next-generation dual PI3K/mTOR inhibitors to transform treatment options across oncology and non-oncology applications.

Company Presentation

1. Ongoing Trial, final data expected H1 2025. Sambandam et al. Clin. Canc. Res., 25(11):3329, 2019
2. Cmiljanovic et al. (submitted). Topical PI3K/mTOR inhibitor PQR309 (Bimiralsib) in actinic keratoses and squamous cell carcinoma.
3. Wind et al. Cancers 2022, 14, 1510Cancers 2022, 14, 1510.
4. Janku et al. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 October 26-30, 2019;
6. Janku et al., Cancers,16(6):1137, 2024.
5. Johnson, F.M., et al., Oncologist, 27(12):1004, 2022
7. Wicki et al. European Journal of Cancer 96 (2018) 6-16
8. Sambandam, V., et al. 2019, Clinical Cancer Research, p. 3276.
9. Bohnacker et al. 2017 Nature Commun. 8:14683:

SUMMARY:
TORQUR AG

PROBLEM

    Topical application:

  • AK (Actinic Keratosis) is a precancerous scaly spot found on sun-damaged skin, also known as solar keratosis and may be considered an early form of cutaneous squamous cell carcinoma
  • Shortcomings with current standard of care for AK due to tolerability, some of which are severe, with recurrence rate of AK of up to 58%

    Oral application:

  • Lack of efficient, tolerable treatment options for many major cancer types

SOLUTION

    Topical application:

  • Innovative prevention of malignant lesion progression of AK by inhibiting PI3K/mTOR pathway1,2
  • Preliminary promising clinical study suggests a high response rate1,3*

    Oral application:

  • Biomarker-based approach for specific cancers4,5
  • Significantly improved safety profile due to alternative dose regimens6,7
  • Excellent results across all key endpoints in pre-clinical models8,9

1. Ongoing Trial, final data expected H1 2025. Sambandam et al. Clin. Canc. Res., 25(11):3329, 2019
2. Cmiljanovic et al. (submitted). Topical PI3K/mTOR inhibitor PQR309 (Bimiralsib) in actinic keratoses and squamous cell carcinoma.
3. Wind et al. Cancers 2022, 14, 1510Cancers 2022, 14, 1510.
4. Janku et al. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 October 26-30, 2019;
6. Janku et al., Cancers,16(6):1137, 2024.
5. Johnson, F.M., et al., Oncologist, 27(12):1004, 2022
7. Wicki et al. European Journal of Cancer 96 (2018) 6-16
8. Sambandam, V., et al. 2019, Clinical Cancer Research, p. 3276.
9. Bohnacker et al. 2017 Nature Commun. 8:14683:

Company Presentation

TORPEDO

Transforming Cancer Treatment

Torpedo develops next-generation radioligand therapies using Terbium-161, a groundbreaking radioisotope, to advance cancer care.

Company Presentation

SUMMARY OF
TORPEDO PHARMACEUTICALS AG

PROBLEM

  • Prostate Cancer affects over 3 million men in the US alone.
  • Poor current Standard of Care with a multitude of side-effects.
  • Survival below 30% for advanced-stage patients.
  • Despite the emergence of targeted radioligand therapies (RLTs), only ~2% of patients have access.

SOLUTION

  • Cutting-edge RLT leveraging the highly potent Terbium-161
  • Limited side effects (safety profile similar to Lutetium-177)3
  • Outperforming current gold standard (177-Lutetium-PSMA-617) across major endpoints (higher efficacy, absorption and survival rates) in animal studies2
  • Swiss Rockets subsidiary Swiss Rockets Medical Group AG is in the process of setting up a supply chain to raw material to ensure access to Terbium-161 for clinical development and commercialization1

1. Schaefer-Schuler A et al. Theranostics, 14: 1830-1840 (2024)
2. Müller et al. EJNMMI 46: 1919-1930 (2019)
3. Baum et al.J Nucl Med 62: 1113–1126 (2021)

1. Schaefer-Schuler A et al. Theranostics, 14: 1830-1840 (2024)
2. Müller et al. EJNMMI 46: 1919-1930 (2019)
3. Baum et al.J Nucl Med 62: 1113–1126 (2021)

Company Presentation
Company Presentation

Current Radio Ligand Therapy CHALLENGES

  • Not all patients respond to current therapy (177Lu-PSMA-617)
  • Some patients show only limited response to current therapy. One of the key reasons for this limited response to Lutetium-177 is the incomplete destruction of the tumors due to insufficient radiation energy

Torpedo SOLUTIONS

  • Preclinical experiments demonstrated the superior therapeutic potential of Terbium-161 over Lutetium-1772
  • Terbium-161 delivered 2.4 times higher radiation dose to tumors, whilst keeping a similar safety profile to Lutetium-1771
  • Clinical data in 6 patients showed either partial response or a stable disease after only one dose of Terbium-1611
  • Other competitors are developing therapies based on Actinium (Ac-225) which has shown serious side effects